Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Duodenoscope Design Aimed at Infection Prevention

Duodenoscope Design Aimed at Infection Prevention News & Analysis News From the Food and Drug Administration First Biosimilar to Treat Cancer In addition, bevacizumab-awwb carries manufacturers, hospitals, and other stake- The FDA has approved the country’s first a boxed warning alerting clinicians and pa- holders to investigate ways to lessen the risk biosimilar for adults with cancer. Bevaci- tients to the increased risk of gastrointesti- of duodenoscope-related infections. zumab-awwb, which will be marketed as nal perforation, surgery and wound- According to the agency, duodeno- Mvasi, has been approved to treat the same healing complications, and hemorrhage. scopes are used in more than 500 000 typesofcancersasitsreferenceproduct,be- potentially life-saving endoscopic retro- vacizumab, which is sold as Avastin. grade cholangiopancreatography proce- Duodenoscope Design Aimed at The drug is a recombinant immunoglob- Infection Prevention dures annually in the United States. The de- ulin G1 monoclonal antibody that binds to A newly designed duodenoscope intended vices are complex, with many small working to reduce patients’ risk of infection has re- vascular endothelial growth factor (VEGF). parts that make them challenging to clean By blocking VEGF’s interaction with its re- ceived FDA approval. anddisinfect.However,FDAofficialssaidthe ceptors, bevacizumab-awwb prevents the benefits of duodenoscope use outweigh the development of new blood vessels that solid http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Duodenoscope Design Aimed at Infection Prevention

JAMA , Volume 318 (17) – Nov 7, 2017

Duodenoscope Design Aimed at Infection Prevention

Abstract

News & Analysis News From the Food and Drug Administration First Biosimilar to Treat Cancer In addition, bevacizumab-awwb carries manufacturers, hospitals, and other stake- The FDA has approved the country’s first a boxed warning alerting clinicians and pa- holders to investigate ways to lessen the risk biosimilar for adults with cancer. Bevaci- tients to the increased risk of gastrointesti- of duodenoscope-related infections. zumab-awwb, which will be marketed as nal perforation,...
Loading next page...
 
/lp/american-medical-association/duodenoscope-design-aimed-at-infection-prevention-v2twyU9NLm
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2017.16043
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the Food and Drug Administration First Biosimilar to Treat Cancer In addition, bevacizumab-awwb carries manufacturers, hospitals, and other stake- The FDA has approved the country’s first a boxed warning alerting clinicians and pa- holders to investigate ways to lessen the risk biosimilar for adults with cancer. Bevaci- tients to the increased risk of gastrointesti- of duodenoscope-related infections. zumab-awwb, which will be marketed as nal perforation, surgery and wound- According to the agency, duodeno- Mvasi, has been approved to treat the same healing complications, and hemorrhage. scopes are used in more than 500 000 typesofcancersasitsreferenceproduct,be- potentially life-saving endoscopic retro- vacizumab, which is sold as Avastin. grade cholangiopancreatography proce- Duodenoscope Design Aimed at The drug is a recombinant immunoglob- Infection Prevention dures annually in the United States. The de- ulin G1 monoclonal antibody that binds to A newly designed duodenoscope intended vices are complex, with many small working to reduce patients’ risk of infection has re- vascular endothelial growth factor (VEGF). parts that make them challenging to clean By blocking VEGF’s interaction with its re- ceived FDA approval. anddisinfect.However,FDAofficialssaidthe ceptors, bevacizumab-awwb prevents the benefits of duodenoscope use outweigh the development of new blood vessels that solid

Journal

JAMAAmerican Medical Association

Published: Nov 7, 2017

There are no references for this article.